Evidence map›Paper›PMID 41496206›Full record

ArticleRedox biology2026

Redox-active nitroxides enhance cisplatin efficacy against cervical cancer.

Carl P Soltau, Debottam Sinha, Lakshita P Patil, Philip M Moseley, Cassie L Rayner, Nigel L Barnett, Derek J Richard, Steven E Bottle, Ian H Frazer, Alexander P Martyn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carl P SoltauSchool of Chemistry and Physics, Queensland University of Technology, 2 George St, Brisbane, QLD, 4000, Australia; Cancer & Ageing Research Program, Centre for Genomics and Personalised Health, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, QLD, 4059, Australia.
Debottam SinhaFrazer Institute, Faculty of Medicine, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Lakshita P PatilFrazer Institute, Faculty of Medicine, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Philip M MoseleyFrazer Institute, Faculty of Medicine, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Cassie L RaynerClem Jones Centre for Regenerative Medicine, Faculty of Health Sciences and Medicine, Bond University, 14 University Drive, Robina, Gold Coast, QLD, 4226, Australia.
Nigel L BarnettClem Jones Centre for Regenerative Medicine, Faculty of Health Sciences and Medicine, Bond University, 14 University Drive, Robina, Gold Coast, QLD, 4226, Australia.
Derek J RichardCancer & Ageing Research Program, Centre for Genomics and Personalised Health, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, QLD, 4059, Australia.
Steven E BottleSchool of Chemistry and Physics, Queensland University of Technology, 2 George St, Brisbane, QLD, 4000, Australia.
Ian H FrazerFrazer Institute, Faculty of Medicine, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
Alexander P MartynCentre for Advanced Imaging and Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Building 57, St Lucia, QLD, 4072, Australia. Electronic address: a.martyn@uq.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin remains the primary treatment for most cervical cancer cases, though its clinical efficacy is hindered by dose-dependent toxicity and incurring chemoresistance. The overexpression of the glucocorticoid receptor (GR) and cellular redox state is linked to increased resistance to chemotherapy in cervical cancer. This study explores the combinations of novel steroidal and nitroxide-based treatments to improve the efficacy of cisplatin against cervical cancer. Two lead nitroxide-functionalised prednisolone hybrids (CS91 and CS187) were identified for their potent anti-proliferative activity in multiple cervical squamous cell carcinoma (SCC) cell lines. These compounds exhibit comparable anti-proliferative activity to the parent nitroxides, while maintaining GR binding capability. When combined with cisplatin, CS91 and CS187 induced a dose-dependent reduction in cell viability across multiple cervical cancer cell lines, which was optimised to preserve above 80 % healthy cell viability but decrease cancer cell viability below 15 %. Mechanistic studies revealed that these compounds raised intracellular reactive oxygen species (ROS) levels, with further enhancement in combination with cisplatin. This combination approach was found to be synergistic, resulting in decreased glutathione (GSH) levels and increased DNA damage compared to cisplatin alone. In summary, nitroxide-based hybrids exhibit potent anti-proliferative effects and potentiate cisplatin efficacy through ROS-mediated mechanisms, offering a promising targeted strategy for cervical cancer treatment.

Indexed as

Antineoplastic AgentsCisplatinNitrogen OxidesPrednisoloneUterine Cervical NeoplasmsCell Line, TumorCell ProliferationCell SurvivalDNA DamageDrug SynergismFemaleGlutathioneHumansOxidation-ReductionReactive Oxygen SpeciesAntineoplastic AgentsCisplatinGlutathioneNitrogen OxidesPrednisoloneReactive Oxygen Species

Identifiers

PMID41496206
PMCPMC12808834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.